Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update and Second Quarter 2013 Financial Results

Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today provided a launch update for PROCYSBI (cysteamine bitartrate) delayed-release capsules and financial results for its second quarter and six months ended June 30, 2013. PROCYSBI Update and Operational Highlights On April 30, 2013, PROCYSBI received marketing approval from the U.S. Food and Drug Administration